Patients with dermatomyositis in the US experience substantial variability in treatment, high glucocorticoid exposure, and significant healthcare utilization.

Brepocitinib significantly boosts global, all secondary dermatomyositis scores in VALOR tr ...

Researchers reported positive results for a novel agent for dermatomyositis from a phase 3 trial today at the 2026 American Academy of Dermatology Annual Meeting in Denver. The results were published ...

The objectives of the treatment of dermatomyositis include improving the physical function by treating muscle weakness and skin disease, as well as addressing any other underlying complications and ...

An investigational monoclonal antibody targeting interferon beta (IFNβ) led to rapid and pronounced reductions in disease activity in adults with dermatomyositis, a randomized phase II study showed.

Please provide your email address to receive an email when new articles are posted on . The study included patients with cutaneous dermatomyositis and those with muscle involvement. Treatment-emergent ...

At 52 weeks, the 30-mg daily oral dose of brepocitinib outperformed the 15-mg dose in a study of patients with dermatomyositis resistant to previous treatments.

Patients with jDM vs aDM show distinct organ patterns, autoantibody profiles, treatment courses, and outcomes.

The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the ...

Children with a rare, debilitating muscle disease could benefit from the findings of new research by experts at UCL and Great Ormond Street Hospital (GOSH). For the study, published in Annals ...

NEW ORLEANS — A monoclonal antibody targeting interferon beta (IFN-beta) provided substantial reductions in the skin lesions associated with dermatomyositis in a double-blind, placebo-controlled phase ...

by Katherine Nowicki Wed, April 23rd 2025 at 10:41 AM Walk strong to cure Juvenile Dermatomyositis (JM) TOPICS: Juvenile Dermatomyositis Fundraiser Sparks Marina Amy Buescher Trisha Buescher Chris ...